APM
NGM

Avidity Partners Management’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Avidity Partners Management’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,798,100
Closed -$23.5M – 109
2022
Q3 		$23.5M Buy
+1,798,100
New +$27.2M 0.48% 49

Other funds holding NGM

CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Avidity Partners Management's NGM Position: Q4 2022 in Review

Avidity Partners Management sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q4 2022, closing a stake of 1,798,100 shares — an estimated $23.5M sold.

Avidity Partners Management first reported a position in NGM in Q3 2022 and held it in 1 quarter. The position peaked at $23.5M in Q3 2022. 124 funds tracked by Wall St. Rank hold NGM as of Q4 2022.

  • Avidity Partners Management reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Avidity Partners Management sold 1,798,100 NGM Biopharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $23.5M.
  • Avidity Partners Management first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q3 2022 and held it in 1 quarter.
  • Avidity Partners Management's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $23.5M in Q3 2022.
  • 124 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on Avidity Partners Management's 13F filing for Q4 2022, filed 14 Feb 2023.